

UnitedHealthcare Pharmacy - PDL Report January 1, 2013

Fully Insured Customers on the Advantage Prescription Drug List (PDL)

ABOUT THIS PDL REPORT




Your PDL Report serves as a summary of updates to your Prescription Drug List (PDL) and pharmacy benefit. In this report, you will find the details of the Jan. 1, 2013 decisions and how they will affect you and your employees.







SUMMARY OF UPDATES












The Jan. 1, 2013 PDL and pharmacy benefit updates represent a small percentage of prescriptions. UnitedHealthcare will send letters notifying any impacted employees of the updates below and provide other medication options to discuss with their physician.

MORE INFORMATION








For a complete list of clinical program updates (Supply Limits and Notification), lower-cost options, and member communication materials, contact your UnitedHealthcare representative.

PDL Decision Rationale Key	
	Cost Savings Opportunity to lower overall class cost. Options are also available.
	Options Available Over-the-counter (OTC) medications available.
	Multiple Product Packaging: Two individual medications packaged together. Combination Medications: One medication combined of two or more already available prescription medications.









Decisions Definition Key	
	Up-Tier
	New Tier Placement
	Select Designated Pharmacy
	Refill & Save Program SM
	Exclusion
	Continued Exclusion (previously Excluded at Launch)

Depression		
		Cymbalta (2007 Rider) Is priced at a premium to other depression therapies. The price of Cymbalta is predicted to increase due to its upcoming patent expiration. Cymbalta will be removed from the Refill & Save Program and will be placed in the Select Designated Pharmacy program. Other lower-cost generics are available.
		Oleptro (2007 Rider) Is an extended-release formulation of its Tier 1 therapeutic equivalent trazodone (generic Desyrel) and costs nearly 13 times more.
High Blood Pressure		
		Dutoprol (2007 Rider) Is a combination of two high blood pressure medications (metoprolol succinate ER and hydrochlorothiazide). It offers sufficient value compared to other class options and will be placed in Tier 2.
		Exforge and Exforge HCT (2007 Rider) Are combination products that cost nearly eight times more than alternative options generic Cozaar and generic Hyzaar combined with amlodipine (generic Norvasc). One of the active ingredients in Exforge, Diovan and Diovan HCT, are expected to go generic in September 2012, giving members more lower-cost options in this class.
High Cholesterol		
		Altprev (2007 Rider) Is an extended-release version of Tier 1 lovastatin and is almost 40 times more expensive than all Tier 1 options in the class.
		Lipitor (brand only – 2007 Rider) Atorvastatin (generic Lipitor) launched in November of 2011 and will continue to be a Tier 1 option.































Neuropathic Pain		
		Gralise (2007 Rider) Previously excluded at launch, is a new once-a-day brand formulation of Tier 1 gabapentin (generic Neurontin) yet costs 14 times more.
Pain		
		Bromday (eye pain – 2007 Rider) Launched as a more expensive patent-extension to Xibrom. In an effort to drive use to the new product Bromday, the manufacturer discontinued Xibrom. Several options exist including generic alternatives in Tier 1 as well as bromfenac (generic Xibrom) in Tier 3.
		ConZip (chronic pain – 2007 Rider) Previously excluded at launch, contains the same active ingredient and is nearly double the cost of extended-release tramadol (generic Ultram ER) available in Tier 1.
		Duexis (arthritis pain – 2007 Rider) Previously excluded at launch, it is ten times more expensive than its over-the-counter components (ibuprofen (generic Motrin) and famotidine (generic Pepcid)). Tier 1 generic equivalents are also available.
		Lazanda (cancer pain – 2007 Rider) Is a nasal spray formulation of fentanyl (Actiq). It offers a new dosage form in its therapeutic class and will be covered in Tier 3.
		Lorzone (muscle pain – 2007 Rider) Previously excluded at launch, has the ingredient as its therapeutic equivalent, generic chlorzoxazone in Tier 1, but costs nearly 13 times more.
		Skelaxin (muscle pain – brand only – 2007 Rider) Costs nearly five times more than other Tier 1 alternatives. Member impact is limited with 59% of members filling only once. Generic Skelaxin (metaxalone) will still be covered in Tier 1.
		Sprix (pain – 2007 Rider) Is a nasal spray that offers a unique formulation for short-term pain to members who cannot take oral medications and will be covered in Tier 3.
Restless Legs Syndrome		
		Horizant (2007 Rider) Previously excluded at launch, this is an extended-release formulation of its therapeutic equivalent, Tier 1 gabapentin (generic Neurontin), yet is nearly 12 times more expensive.
Skin Conditions		
		Aqua Glycolic HC (dermatitis – 2007 Rider) Previously excluded at launch, this is a multiple product package that is therapeutically equivalent to its individual components , Tier 1 generic Hytone and OTC Aqua Glycolic.
		Clindagel (acne – 2007 Rider) The package size of Clindagel was increased to a supply greater than 30 days. With the same ingredient as generic Cleocin-T in Tier 1, Clindagel offers no additional value.
		Metrogel 1% (rosacea – 2007 Rider) Is six times more expensive than its generic equivalent in Tier 1, metronidazole gel 0.75%.
		ProCort (dermatitis – 2007 Rider) Previously excluded at launch, is nearly three times more expensive than its generic equivalent hydrocortisone/pramoxine (generic Analpram E) in Tier 1.
		Promiseb Complete Kit (dermatitis – 2007 Rider) Previously excluded at launch, this is a multiple product package that contains Tier 3 Promiseb and an OTC skin cleanser, which together cost less than the kit itself.

Skin Conditions, continued

		Rosadan Kit-gel (rosacea – 2007 Rider) Previously excluded at launch, this is a multiple product package that contains a gel formulation of already excluded Rosadan Kit . Members can choose to move to Tier 1 generic Metrogel.
		Sumaxin CP (acne – 2007 Rider) Previously excluded at launch, this is a multiple product package containing a Tier 1 and OTC medication (sulfacetamide sodium / sulfur (generic Sulfatol) and a skin cleanser).
		Trianex (dermatitis – 2007 Rider) Previously excluded at launch, is a branded version of Tier 1 triamcinolone (generic Aristocort). It contains the same active ingredient yet costs nearly 16 times more .
		Uramaxin GT Kit (toenail infections – 2007 Rider) Previously excluded at launch, this is a multiple product package that contains urea 40% (a generic in Tier 1), and OTC Keradan cream that offers no additional clinical value .

Additional Exclusions¹

		Astelin (nasal allergies – brand only – 2007 Rider) Is a nasal spray formulation in a class filled with other OTC options that treat allergies for \$10-15 . Tier 1 options are also available.
		Bepreve (eye allergies – 2004 Rider) Has increased in cost by almost 40% in the last 18 months and has OTC therapeutic equivalents (Zaditor) available for approximately \$13.
		Flo-Pred (inflammation – 2007 Rider) Previously excluded at launch, this is a special flavored brand-name medication that contains the same active ingredient as Tier 1 prednisolone yet is nearly 21 times more expensive .
		Generess FE (contraceptive – 2007 Rider) Previously excluded at launch, this is a chewable contraceptive formulation that is priced at a premium because of its unique form . It offers no additional clinical value in a class with nearly 30 Tier 1 options.
		Optivar (eye allergies – brand only – 2004 Rider) Has an OTC equivalent, Zaditor, available for around \$13 as well as other Tier 3 options.
		Pedipirox-4 (toenail infections kit – 2007 Rider) Previously excluded at launch, this is a multiple product package that contains the same active ingredient as Tier 1 ciclopirox (generic Penlac) plus alcohol-based pads.
		RibaPak (Hepatitis C – 2007 Rider) Is a pre-packaged formulation of generic Tier 1 ribavirin and costs nearly four times as much .
		Staxyn (erectile dysfunction – 2007 Rider) Previously excluded at launch, this is an orally disintegrating formulation of therapeutically equivalent Levitra in Tier 3 yet offers no additional clinical value compared to other covered alternatives.
		Zegerid capsule (ulcers, heartburn, and reflux – 2004 Rider) Costs nearly 15 times more than its generic options in Tier 1 and is equivalent to Zegerid OTC. Since July 2010, Zegerid utilization has dropped significantly due to the number of Tier 1 and OTC options.

Additional Up-Tiers		
		Actonel (osteoporosis) Is priced at a premium to Tier 1 generic alendronate (Fosamax).
		Condylox gel (viral Infection) Is priced at a premium compared to therapeutically equivalent Tier 1 podofilox solution (generic Condylox liquid).
		Enablex (overactive bladder) Is priced at a premium to its Tier 1 alternative, generic oxybutynin. Tier 2 options are also available.
		Levoxyl (thyroid hormone replacement) A branded alternative to generic levothyroxine yet is priced nearly twice as much as Tier 1 generic Synthroid .
		Januvia (diabetes) Has Tier 2 options available, Onglyza and Tradjenta, and does not offer sufficient value to be placed in Tier 2 . It will move to Tier 3.

Health Care Reform - Contraceptives

Starting August 1, 2012, the Patient Protection and Affordable Care Act or “health reform law” requires pharmacy benefit contraception coverage for all self-funded plans beginning on their renewal date. Specifically, the law requires coverage of FDA-approved contraceptive methods for women at 100 percent, without charging a copayment, coinsurance or deductible, when filled at a network pharmacy.

To satisfy this requirement, UnitedHealthcare has created the following list of Tier 1 (lowest-cost) contraceptives which can be found on the contraceptives tab. **Upon your renewal, these contraceptives will be available at no cost to members on both standard and high-deductible or consumer-driven health (CDH) plans.** Please note this list may change depending on your renewal date, and whether you have a custom drug list.

Please contact your UnitedHealthcare representative prior to your renewal date, and confirm you would like to cover contraceptives at \$0 cost-share. This new benefit will not change your coverage, but only move Tier 1 contraceptives to \$0 cost-share. If you have grandfathered status or meet the federal requirements for religious exemption (including safe harbor) as defined by the health reform law, and do not want contraceptive coverage, please contact your UnitedHealthcare representative for further direction.

THIS IS THE END OF YOUR REPORT



For more information

Visit www.uhc.com/pharmacy or contact your UnitedHealthcare representative

Please note: You may need to add language to your Summary Plan Description (SPD) in order to implement some updates. Ask your UnitedHealthcare representative if you need assistance updating your SPD.

¹ For customers that implemented the Exclude at Launch Program, the green icons indicate which medications were excluded at launch and will have minimal to no member impact. For customers that did not, medications are currently in Tier 3.

Please Note: For customers not on the 2007 Pharmacy Rider, exclusions based on the 2007 Rider will not be implemented until customer's renewal of the new pharmacy rider and as allowed by state regulation.